Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations

Lotte Westerink*, Jelmer L. J. Nicolai, Carl Samuelsen, Hans J. M. Smit, Pieter E. Postmus, Ingolf Griebsch, Maarten J. Postma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

36 Downloads (Pure)

Abstract

BACKGROUND: The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that have common epidermal growth factor receptor (EGFR) mutations has changed radically in the last decade. The availability of these treatment options has an economic impact, therefore a budget impact analysis was performed.

METHODS: A budget impact analysis was conducted from a Dutch healthcare perspective over a 5-year time horizon in EGFR-mutant NSCLC patients receiving first-line afatinib (Gilotrif®) versus first-line osimertinib (Tagrisso®), followed by subsequent treatments. A decision analysis model was constructed in Excel. Scenario analyses and one-way sensitivity analysis were used to test the models' robustness.

RESULTS: Sequential treatment with afatinib versus first-line treatment with osimertinib showed mean total time on treatment (ToT) of 29.1 months versus 24.7 months, quality-adjusted life months (QALMs) of 20.2 versus 17.4 with mean cost of €108,166 per patient versus €143,251 per patient, respectively. The 5-year total budget impact was €110.4 million for the afatinib sequence versus €158.6 million for the osimertinib sequence, leading to total incremental cost savings of €48.15 million.

CONCLUSIONS: First-line afatinib treatment in patients with EGFR-mutant NSCLC had a lower financial impact on the Dutch healthcare budget with a higher mean ToT and QALM compared to osimertinib sequential treatment.

Original languageEnglish
Pages (from-to)931-943
Number of pages13
JournalEuropean Journal of Health Economics
Volume21
Issue number6
DOIs
Publication statusPublished - 1-Aug-2020

Keywords

  • Budget impact
  • Afatinib
  • Osimertinib
  • Treatment sequencing
  • I15
  • I18
  • OPEN-LABEL
  • PHASE-III
  • GEFITINIB
  • ADENOCARCINOMA
  • CHEMOTHERAPY
  • GEMCITABINE
  • RESISTANCE
  • TRIAL

Cite this